Jazz Pharmaceuticals’ Carr exercises 1,250 options

Q: What options did Patricia Carr exercise in JAZZ?

Carr exercised 1,250 non-qualified stock options at an exercise price of $140.03 per share on November 4, 2026, acquiring 1,250 ordinary shares. The option transaction reports 3,000 options following the exercise.

The option transaction reports 3,000 options following the exercise, alongside sales reported at two distinct per-share prices.

Available on EDGAR 11/06/2026 - 05:20 PM EST Accepted by SEC EDGAR 11/06/2026 - 05:19 PM EST

Filing Impact

(Neutral)

Filing Sentiment

(Negative)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Jazz Pharmaceuticals plc reported that its SVP, Chief Accounting Officer Patricia Carr exercised 1,250 non-qualified stock options at an exercise price of $140.03 per share on November 4, 2026, acquiring 1,250 ordinary shares. That day, Carr sold 1,250 ordinary shares at $231.37 per share and 163 ordinary shares at $231.27 per share. The option transaction reports 3,000 options following the exercise. No Rule 10b5-1 plan is reported.

Insider Trade Summary

Exercise and sale activity reported; no spread calculated

Exercise and Sale 4 txns

Insider Carr Patricia

Role SVP, Chief Accounting Officer

Sold 1,413 shs ($327K)

Approx. gross sale proceeds $327K

Approx. exercise cost $175K

Share of Position Sold 17.8%

Type	Security	Shares	Price	Value
Exercise	Non-Qualified Stock Option (right to buy) ^F2	1,250	$0.00	$0.00
Exercise	Ordinary Shares ^F1	1,250	$140.03	$175K
Sale	Ordinary Shares	1,250	$231.37	$289K
Sale	Ordinary Shares	163	$231.27	$38K

Holdings After Transaction: Non-Qualified Stock Option (right to buy) — 3,000 contracts (Direct); Ordinary Shares — 6,512 shares (Direct)

Holdings Before and After: Non-Qualified Stock Option (right to buy), 4,250 to 3,000 contracts (Direct); Ordinary Shares, 6,675 to 6,512 shares (Direct)

Other Insiders: 2 other insiders reported open-market sales of this stock in the 30 days up to this filing.

Footnotes (2)

F1. The Reporting Person acquired 163 ordinary shares under a Section 423 Employee Stock Purchase Plan on May 29, 2026.
F2. These options are granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vest over four years measured from the grant date, February 28, 2019, with 1/4th vesting on the first anniversary of the grant date and the remainder vesting in 36 equal monthly installments thereafter.

Key Figures

Options exercised: 1,250 options Exercise price: $140.03 per share Ordinary shares sold: 1,250 shares +4 more

7 metrics

Options exercised 1,250 options November 4, 2026

Exercise price $140.03 per share November 4, 2026

Ordinary shares sold 1,250 shares November 4, 2026

Sale price $231.37 per share November 4, 2026

Ordinary shares sold 163 shares November 4, 2026

Sale price $231.27 per share November 4, 2026

Options following transaction 3,000 options Following the November 4, 2026 exercise

Key Terms

Non-Qualified Stock Option, Section 423 Employee Stock Purchase Plan, 2011 Equity Incentive Plan

3 terms

Non-Qualified Stock Option technical

"Non-Qualified Stock Option (right to buy)"

A non-qualified stock option (NSO) is a contract that lets an employee or service provider buy company shares at a fixed price for a set period, like a voucher to purchase stock later at today’s price. It matters to investors because exercising NSOs creates ordinary income for the holder and can increase share count, affecting a company’s earnings and ownership mix; think of it as a future sale that can dilute existing shareholders and has immediate tax consequences for the recipient.

Section 423 Employee Stock Purchase Plan technical

"under a Section 423 Employee Stock Purchase Plan"

2011 Equity Incentive Plan technical

"pursuant to the Issuer's 2011 Equity Incentive Plan"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many JAZZ shares did Patricia Carr sell on November 4, 2026?

Patricia Carr, SVP, Chief Accounting Officer, reported selling 1,250 ordinary shares at $231.37 per share and 163 ordinary shares at $231.27 per share on November 4, 2026. No Rule 10b5-1 plan is reported.

What options did Patricia Carr exercise in JAZZ?

Carr exercised 1,250 non-qualified stock options at an exercise price of $140.03 per share on November 4, 2026, acquiring 1,250 ordinary shares. The option transaction reports 3,000 options following the exercise.

How did Patricia Carr's JAZZ options vest?

The options were granted under the 2011 Equity Incentive Plan and vest over four years from the February 28, 2019 grant date: one-quarter on the first anniversary, with the remainder vesting in 36 equal monthly installments.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Carr Patricia

(Last)

(First)

(Middle)

5TH FL, WATERLOO EXCHANGE

WATERLOO RD

(Street)

DUBLIN 4

(City)

(State)

(Zip)

IRELAND

(Country)

2. Issuer Name and Ticker or Trading Symbol
Jazz Pharmaceuticals plc [ JAZZ ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	SVP, Chief Accounting Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
11/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Ordinary Shares	11/04/2026		M		1,250	A	$140.03	7,925⁽¹⁾	D
Ordinary Shares	11/04/2026		S		1,250	D	$231.37	6,675	D
Ordinary Shares	11/04/2026		S		163	D	$231.27	6,512	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Non-Qualified Stock Option (right to buy)	$140.03	11/04/2026		M			1,250	⁽²⁾	02/27/2029	Ordinary Shares	1,250	$0.0	3,000	D

Explanation of Responses:

1. The Reporting Person acquired 163 ordinary shares under a Section 423 Employee Stock Purchase Plan on May 29, 2026.

2. These options are granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vest over four years measured from the grant date, February 28, 2019, with 1/4th vesting on the first anniversary of the grant date and the remainder vesting in 36 equal monthly installments thereafter.

	By: /s/Paz Dizon, as attorney in fact For: Patricia Carr	11/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR